The full form of CEPI is Coalition for Epidemic Preparedness Innovations.

Epidemic diseases affect us all. They do not respect borders. CEPI is a innovative global partnership between public, private, philanthropic, and civil society organisations. We’re working together to accelerate the development of vaccines against emerging infectious diseases and enable equitable access to these vaccines for people during outbreaks.

CEPI is a Norwegian Association. The primary governing body is the Board, which has 12 voting members (four investors and eight independent members representing competencies including industry, global health, science, resource mobilisation, finance) and five observers.

The Board is advised on decisions, such as prioritising pathogens and selecting development partners, by our Scientific Advisory Committee.

We have four Board Committees: Executive and Investment, Nominations, Compensation, Diversity and Inclusion, Audit and Risk, and Equitable Access, with members of our Board Committees listed below. Other Board members or experts may be called upon as advisers or observers as needed.

CEPI was founded in Davos by the governments of Norway and India, the Bill & Melinda Gates Foundation, Wellcome, and the World Economic Forum.

To date, CEPI has secured financial support from Australia, Austria, Belgium, the Bill & Melinda Gates Foundation, Canada, Denmark, the European Commission, Finland, Germany, Hungary, Italy, Japan, Kuwait, Lithuania, Luxembourg, Mexico, Netherlands, New Zealand, Norway, Panama, Saudi Arabia, Serbia, Singapore, Switzerland, United Kingdom, USAID, Ethiopia, The Republic of Korea, Indonesia, and Wellcome.

Additionally, CEPI has also received support from private sector entities as well as public contributions through the UN Foundation COVID-19 Solidarity Response Fund.

US $800m is still urgently needed to advance our COVID-19 vaccine efforts.

Close collaboration with global partners is also crucial to the success of our work to develop vaccines against emerging infectious diseases. That’s why work with industry, regulators, and other bodies to ensure that any vaccines we develop get licensed and can reach the people who need them.